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DNA inter-strand crosslinks (ICLs) threaten genomic stability by creating a physical barrier to DNA 
replication and transcription. ICLs can be caused by endogenous reactive metabolites or from 
chemotherapeutics. ICL repair in humans depends heavily on the Fanconi Anaemia (FA) pathway. A key 
signalling step of the FA pathway is the mono-ubiquitination of Fanconi Anaemia Complementation 
Group D2 (FANCD2), which is achieved by the multi-subunit E3 ligase complex. FANCD2 mono-
ubiquitination leads to the recruitment of DNA repair proteins to the site of the ICL. The loss of FANCD2 
mono-ubiquitination is a common clinical feature of FA patient cells. Therefore, molecules that restore 
FANCD2 mono-ubiquitination could lead to a potential drug for the management of FA. On the other 
hand, in some cancers, FANCD2 mono-ubiquitination has been shown to be essential for cell survival. 
Therefore, inhibition of FANCD2 mono-ubiquitination represents a possible therapeutic strategy for 
cancer specific killing. We transferred an 11-protein FANCD2 mono-ubiquitination assay to a high-
throughput format. We screened 9,067 compounds for both activation and inhibition of the E3 ligase 
complex. The use of orthogonal assays revealed that candidate compounds acted via non-specific 
mechanisms. However, our high-throughput biochemical assays demonstrate the feasibility of using 
sophisticated and robust biochemistry to screen for small molecules that modulate a key step in the FA 
pathway. The future identification of FA pathway modulators is anticipated to guide future medicinal 
chemistry projects with drug leads for human disease.
The significance of FANCD2 mono-ubiquitination in Fanconi anaemia. Bi-allelic germline muta-
tions in one of 22 genes (FANCA-FANCW) result in FA, a rare genetic disorder which often leads to progressive 
bone marrow failure, myelogenous malignancies and squamous cell carcinoma, congenital abnormalities and 
reduced fertility1–5 (with the exceptions of FANCB, which is X-linked6, and FANCR/RAD51, which is autosomal 
dominant7). FA is typically diagnosed with a chromosome breakage test8,9. Most FA patients have mutations 
in FANC genes that are required for FANCD2 mono-ubiquitination10, to the extent that analysis of FANCD2 
mono-ubiquitination in fibroblasts and peripheral blood mononuclear cells is a diagnostic FA assay11. Therefore, 
compounds which can restore FANCD2 mono-ubiquitination could be beneficial to slow the progression of 
FA-related symptoms. Despite the critical importance of FANCD2 mono-ubiquitination in the biology of FA, 
recent work has demonstrated that FANCD2 mono-ubiquitination can be uncoupled from nuclear foci formation 
via the methyl-binding domain of FANCD2 that binds H4K20me212.
There are currently neither systemic and tailored treatments available for FA, nor is there a cure. A recent 
milestone towards a tailored FA treatment was the successful engraftment of autologous lenti-virus-mediated 
corrected haematopoietic stem cells in FA patients13. This study demonstrates the viability of gene therapy for the 
haematopoietic system in FA patients, however the elevated cancer risk for the rest of the body3 would presuma-
bly remain high. Complementary approaches to gene therapy are also being investigated. There are clinical trials 
with metformin (clinical trials identifier NCT03398824) and quercetin (clinical trials identifier NCT01720147) 
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in progress to identify interventions that could improve manifestations of FA, notably haematological response. 
TGF-β inhibition is also being investigated as a mechanism of rescue of haematopoiesis in FA14. These projects 
are promising, and they represent a major milestone for research into treatments for FA. However, these small 
molecule strategies do not specifically target the FA pathway and instead seek to alleviate indirect mechanisms 
of decreased haematopoiesis in FA; e.g. the presence of ICL-inducing aldehydes or reactive oxygen species. The 
small molecule trials may eventually be extended to analyse if there is an effect on cancer risk in FA.
The significance of FANCD2 mono-ubiquitination in malignancies
Increased expression of FANCD2 has been observed in breast and uterine cancers with either BRCA1/2 alter-
ations or decreased homologous recombination (HR) status15. Also FANCD2 expression positively correlates 
with ovarian carcinoma grade and expression of the proliferative marker Ki-6715. Increased FANCD2 expression 
has also been observed in melanoma16. Further, the loss of FANCD2 mono-ubiquitination has been shown to be 
synthetic lethal with silencing or mutation of BRCA115 or BRCA215,17. Similarly, simultaneous loss of USP1 – the 
protein required for deubiquitination of FANCD218 – is synthetic lethal with loss of BRCA119. Further, deple-
tion of FANCI, the binding partner of FANCD2, is also synthetic lethal with silencing or mutation of BRCA1 or 
BRCA215. Therefore, small molecule-mediated inhibition of the proteins required for the regulated ubiquitination 
and deubiquitination of FANCD2/FANCI represents a promising strategy to induce cancer-specific killing. There 
is already clinical precedent for the synthetic lethal approach with PARP inhibitors approved as monotherapies 
for BRCA-mutated cancers – germline or somatic – by the FDA and EMA20.
Molecular biology of FANCD2 mono-ubiquitination
The FA pathway maintains genomic stability through the repair of ICLs21,22 in addition to stabilising stalled rep-
lication forks23,24 and the removal of DNA-RNA hybrids25. One of the first steps of ICL repair via the FA pathway 
is the coordinated mono-ubiquitination of the heterodimer components FANCD2 and FANCI when bound to 
DNA26,27. FANCD2:FANCI mono-ubiquitination is performed by the “FA core complex”, a multi-subunit E3 
ligase complex (Fig. 1a). The core complex is comprised of a ubiquitin E3 RING ligase – FANCL – which is part 
of a sub-complex with FANCB and FAAP100 (FANC-B-L-100) of stoichiometry 2:2:226–30 and a ubiquitination 
substrate adaptor composed of FANCC, FANCE and FANCF (FANC-C-E-F). The core complex also contains 
FANCA, FANCG and FAAP20 (FANC-A-G-20), of which FANCA is mutated in most cases of FA and is required 
for FANCD2 mono-ubiquitination in cells. FANCA has been shown to be important for single strand annealing, 
strand exchange31 and nuclear import of other core complex components32, however no direct biochemical mech-
anism of FANCA in FANCD2 or FANCI mono-ubiquitination has been demonstrated.
The search for inhibitors of the FA core complex has previously been investigated using genetic, biochem-
ical and cell-free extract approaches33–38. A cell-based screen exploited the readout of EGFP-tagged FANCD2 
(in a FANCD2-deficient cell line, PD2039), which localises to DNA damage after treatment with cisplatin33. 
The absence of FANCD2 foci formation indicated that a compound had interfered with the ability of the FA 
core complex to ubiquitinate FANCD2, as mono-ubiquitination of FANCD2 was suggested to be required for 
FANCD2 foci formation40. The study identified the natural compound curcumin as the lead hit33. The same cell 
line was used in a similar screen that identified a number of hits that inhibited EGFP-FANCD2 foci formation 
via mechanisms other than the canonical FA pathway, such as the CHK1 pathway or the proteosome34. Another 
set of investigations found 2,3-dichloro-5,8-dihydroxy-1,4-naphthoquinone and analogs of curcumin as inhib-
itors of FANCD2 mono-ubiquitination using a Xenopus egg extract assay35,36. Two different studies have used 
Figure 1. (a) Illustration of Fanconi anaemia core-complex mediated ubiquitination of FANCD2 with the 11 
proteins used in the inhibitor assay, and (b) read out of core complex-mediated ubiquitination of FANCD2 in 
the proximity assay. When b-ubiquitin is covalently conjugated to GST-FANCD2 they bind the streptavidin-
coated donor beads and the anti-GST coated acceptor beads respectively, hence bringing the two bead types 
into close proximity. When the two bead types are in close proximity – due to FANCD2 mono-ubiquitination 
– excitation of the donor bead at 680 nm results in the transfer of an oxygen singlet to the acceptor bead. The 
acceptor bead then emits detectable light between 520–620 nm. Figure created with BioRender.
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biochemical approaches to identify inhibitors of the FA pathway. The first biochemical study used a fragment 
library and a biophysical approach to identify inhibitors of FANCT which resulted in three compounds that 
were able to inhibit FANCD2 ubiquitination reactions with recombinant proteins. The reaction contained the 
FANCD2, FANCL and FANCT and the compounds inhibited at 1–4 mM41. The second assay used homoge-
nous time-resolved fluorescence to assay for compounds that inhibit auto-ubiquitination of the FANCL RING 
domain. The auto-ubiquitination was used as a surrogate for FANCD2 mono-ubiquitination and in characteri-
zation of the compounds, two hits were found to induce a range of cellular phenotypes consistent with inhibition 
of FANCD237.
Despite the critical importance of FANCD2 mono-ubiquitination for diagnosing FA and defining the genetic 
subtypes, there is no reagent which gives a direct read out of only the mono-ubiquitinated or non-ubiquitinated 
form of FANCD2. Therefore, an antibody raised against FANCD2 is used with low-throughput western blots to 
measure ratios of mono- and non-ubiquitinated FANCD2, which differ by 8.6 kDa. A reagent which can rapidly 
and directly measures FANCD2 mono-ubiquitination in patient samples would be a game changer for diagnos-
tics and the ability to screen for drugs that modulate FANCD2 mono-ubiquitination. To overcome the latter 
and to facilitate drug screening, we have designed a novel high-throughput biochemical compound screen assay 
(Fig. 1b), which captures much of the complexity of the FA core complex – six of nine FA core complex proteins – 
plus the heterodimeric FANCD2-FANCI substrate and DNA, which is required for biologically relevant FANCD2 
mono-ubiquitination. In total, the assay uses 11 recombinant proteins. This assay has been used to contribute new 
methodology to probe for activators and inhibitors of the FA core complex.
Results and Discussion
Assay development. The inhibitor assay includes recombinant ubiquitin, ubiquitin activating enzyme, 
FANCT, FANC-B-L-100, FANC-C-E-F, FANCI, FANCD2 and dsDNA41 (Fig. 2a). For the activator assay, the 
activity stimulating adaptor complex FANC-C-E-F is omitted to give a baseline FANCD2-ubiquitination signal 
which enables a greater dynamic range to detect activation of the E3 ligase sub complex FANCB-L-100 (Fig. 2b,c). 
These two assays were used to screen 9,067 compounds (Sup. Fig. 1) demonstrating that high-throughput bio-
chemical screens with the FA core complex are possible. The gel-based FANCD2 mono-ubiquitination assay that 
we published previously26 was modified to give a chemi-luminescent readout using a proximity assay (Materials 
and methods) (Fig. 1b). The purified proteins in the mono-ubiquitination assays used for the high-throughput 
screen are biotinylated-ubiquitin (b-ubiquitin), His-UBE1, FANCT, Flag-FANCB, FANCL, FAAP100, MBP-
FANCC, FANCE, FANCF, GST-XlFANCD2 and Flag-XlFANCI. The assay was calibrated for maximal signal to 
background and for an optimal dynamic range within which small molecule modulators could be detected in a 
384-well plate format. A number of variables were tested, notably including (1) the amounts of GST-FANCD2 
(Fig. 2d) and b-ubiquitin (Fig. 2e), (2) the amount of core complex to GST-FANCD2, and (3) the incubation time 
with the beads (Fig. 2a). The addition of the beads also stops the mono-ubiquitination reaction, most likely due to 
steric hindrance given the greater size of the beads compared to the GST-FANCD2 and b-ubiquitin.
In order to attribute the 520–620 nm emission from the assay to ubiquitination of FANCD2, a competition 
assay using HA-tagged ubiquitin that cannot bind the donor beads, was performed. This was achieved with the 
titration of HA-ubiquitin through the proximity assay (Fig. 2f). 31.8 nM of HA-Ubiquitin was required to inhibit 
50% of the signal generated from 30 nM of biotinylated ubiquitin (R2 = 0.991), demonstrating that the signal 
emitted at 520–620 nm is due to the conjugation of ubiquitin onto FANCD2.
FANCD2 mono-ubiquitination activator screen. Currently there is no specific treatment for FA that 
directly targets the biochemical cause of the condition. More than 90% of FA patients mutations occur in genes 
with established roles in FANCD2 mono-ubiquitination9,10,42. These mutations typically result in a reduction or 
loss of FANCD2 mono-ubiquitination and defective repair of ICLs6,11,43–47. We performed a high throughput 
screen for small molecule activators of the FANCD2 mono-ubiquitination, which lacks the substrate adaptor 
(FANC-C-E-F) (Fig. 2b,c). The 9,067 compounds tested (see Materials and Methods) in the activator assay were 
screened in duplicate and hits were selected at a Z-score cut off of >2 (FDR = 0.0025). Forty-five compounds pro-
duced a Z-score >2 and were investigated further (Fig. 3a). We used the substrate adaptor (FANC-C-E-F) protein 
complex as the most appropriate available positive control as there is no small molecule activator of FANCD2 
mono-ubiquitination available. These preliminary hits were counter-screened by testing for interference with 
the excitation-emission properties of the beads, as opposed to modulation of FANCD2 mono-ubiquitination 
used in the assay (Sup. Fig. 2a). This bead interference assay was performed by incubating these compounds 
with biotinylated-GST and the proximity assay beads. Following the primary screen, putative hit compounds 
were next analysed over a 9-point dose response curve and quantified using the proximity assay (Fig. 3b,c). The 
FDA-approved compound subset contained some blue coloured compounds which generated signals many-fold 
higher than the FANCC-E-F positive controls. These were excluded as false positive activators (Sup. Fig. 2a). 
Only four compounds (CA11, CA16, CA33 and CA34) showed weak concentration-dependent activation using 
the proximity assay without false-positive activation in the bead interference assay. These four compounds were 
tested by western blot and none were shown to increase FANCD2 ubiquitination compared to controls (Fig. 3d). 
While we did not identify any compounds that increased the levels of FANCD2 mono-ubiquitination, we have 
demonstrated that it is possible to perform high-throughput activator screens with biochemical approaches using 
the direct target that is defective in nearly all FA patients. Subsequent iterations of this activator screen may 
benefit from screening all the scaffold compounds which would enable extensive structure-activity-relationship 
analysis to be performed that may identify an activating chemotype. Similarly, future approaches to find activators 
of FANCD2 mono-ubiquitination with this assay may include patient mutant variants of FANC-C-E-F or the 
addition of FANC-A-G-20. However, FANC-A-G-20 was not included in this screen as it has no detectable effect 
on FANCD2 mono-ubiquitination in our reconstituted biochemical system26.
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Figure 2. FANCD2-mono-ubiquitination proximity assay parameters. (a) Time point ubiquitination assay 
perform using the proximity assay. (b) Demonstration of the controls used for the FANCD2-ubiquitination 
activator screen. The first condition “complete reaction” represent the FANCD2 mono-ubiquitination reaction 
with FANCT, FANC-B-L-100, FANC-C-E-F, FANCI, FANCD2 and dsDNA. The second condition and third 
conditions omit the substrate adaptor FANC-C-E-F (Z′ = 0.57) and ATP respectively. (c) Implementation of 
the two assay conditions to screen for inhibitors and activators of FANCD2 mono-ubiquitination. Arrows 
highlight that maximal ubiquitination levels will be exploited for the identification of inhibitors and basal levels 
of ubiquitination will be exploited for the identification of activators. (d) Titration of GST-FANCI-D2 complex 
through the proximity assay. (e) Titration of biotinylated-ubiquitin through the FANCD2-ubiquination proximity 
assay. (f) Titration of HA-Ubiquitin through the proximity assay of FANCD2-ubiquination, inhibiting the signal 
by 50% at a concentration of 31.8 nM. (g) Titration of TAK243, which is a ubiquitin-activating-enzyme (UbE1) 
inhibitor, through the proximity assay. TAK243 is used as an inhibitor control for the inhibitor screen. (h) 
Demonstration of the controls used for the FANCD2-ubiquitination inhibitor screen, Z′ = 0.79.
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FANCD2 mono-ubiquitination inhibitor screen. Prior to performing the inhibitor screen, we identified 
a positive control small molecule inhibitor of the recombinant FANCD2 mono-ubiquitination reaction. The com-
pound TAK243 is a small molecule that covalently binds to the C-terminus of ubiquitin and occupies the adeny-
late (AMP)-binding site of UBE138. TAK243 was a highly potent inhibitor of the FANCD2 mono-ubiquitination 
reaction with >50% inhibition at 0.3 µM (Fig. 2g,h).
We performed a high throughput screen for inhibitors of FANCD2 mono-ubiquitination with the proximity 
assay using the same 9,067 small molecules screened in duplicate in the activator screen. Thirty-six compounds 
with a Z-score < −2 and were selected for further investigation (Fig. 4a). Similar to the activator screen, these 
preliminary hits were counter-screened testing for interference with the bead assay (Sup. Fig. 2b) and over a 
Figure 3. Primary screen for activators of FANCD2 mono-ubiquitination in the absence of FANC-C -E -F. 
(a) All compounds screened in duplicate plotted as Z scores and presented on a per library representation. 
(b) Nine-point titration of 47 activator hits. (c) Area under curve plot calculated from the curves in 3b, 
demonstrating activation potency for each compound. (d) Cropped images from western blot analysis of 4 
activator hits for an effect on the FANCD2 mono-ubiquitination assay with recombinant protein. Positive 
(Complete Core Complex) and negative (DMSO) controls are shown on the far-left panel. The four activator 
hits from the secondary screen were analysed with FANCD2-ubiquitination assay (without FANC-E-F) 
visualised on western blot by probing with streptavidin to detect biotinylated-ubiquitin. Three concentrations of 
the compounds were used; 1 µM, 10 µM and 100 µM.
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9-point dose response (Fig. 4b,c, Sup. Table 1). Compounds that showed dose-dependent inhibition of FANCD2 
mono-ubiquitination greater than their effect on bead interference were then analysed for inhibition of FANCD2 
mono-ubiquitination by western blot (Fig. 4d, Sup. Fig. 4). Twenty-five compounds were tested (Sup. Fig. 1), 
and 19 inhibited (>80% compared to DMSO) FANCD2 mono-ubiquitination. Therefore, we sought to test 
for specificity of these compounds for the FA pathway by investigating if the highest ranking 25 compounds 
inhibited another recombinant ubiquitination reaction. We tested the same 25 compounds for inhibition of 
Figure 4. Primary screen for inhibitors of FANCD2 mono-ubiquitination. (a) All compounds screened in 
duplicate plotted as z-scores and presented on a per library representation. (b) Nine-point titration of 36 
inhibitor hits. (c) Area under curve plot calculated from the curves in 4b, demonstrating activation potency 
for each compound. (d) Cropped images from western blot analysis of 32 inhibitor hits for an effect on the 
FANCD2 mono-ubiquitination assay with recombinant protein. The hits were analysed with FANCD2-
ubiquitination assay visualised on western blot by probing with streptavidin to detect biotinylated-ubiquitin.
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mono-ubiquitination of PCNA by UbcH5c (Fig. 4d, Sup. Fig. 4). Eighteen compounds did not inhibit PCNA 
ubiquitination (≤ 0% compared to DMSO). In total, 13 compounds inhibited FANCD2 mono-ubiquitination 
(> 80%) but had no effect on PCNA ubiquitination.
Cell-based assays. The twenty-five compounds that appeared to selectively inhibit the FANCD2 
mono-ubiquitination proximity assay were next tested in cell-based assays. The simultaneous loss of FANCD2 
or FANCD2 ubiquitination with BRCA1 deficiency has been shown to be synthetic lethal15. Therefore, we 
tested our preliminary inhibitors for the ability to kill BRCA1-deficient cells preferentially over isogenic 
BRCA1-proficient controls. To achieve this we exploited the triple negative breast cancer cell line SUM14948 
with a homozygous loss of function mutation in BRCA1 (c.2288delT, p.N723fsX13) and the daughter cell line, 
SUM149.B1.S* with one allele containing a secondary restoration of function mutation (an 80-bp BRCA1 dele-
tion, c.[2288delT;2293del80])49. Twenty-five compounds were tested at 10 µM for preferential cytotoxicity in the 
BRCA1-deficient SUM149 (Fig. 5). The positive control compound, the PARP inhibitor olaparib, preferentially 
killed SUM149 cells over SUM149.B1.S* (33.3% vs 78.1%). Two compounds, showed a preferential killing effect 
of BRCA1-negative SUM149 cells, despite also showing toxicity in the B1.S* control at the concentration (10 µM) 
tested (CI04, p = 0.001 [SUM149, 28.7% survival vs SUM149 B1.S*, 55.7% survival], CI27 p = 0.011 [SUM149, 
18.4% survival vs SUM149 B1.S*, 43.7% survival]). However, CI27 did not reduce FANCD2 mono-ubiquitination 
in cells as measured by western blot (Sup. Fig. 3), suggesting that any preferential killing of BRCA1-deficient cells 
is not likely to be via specific inhibition of the FA core complex. CI04 was not investigated by western blot of cell 
extract as it did not specifically inhibit FANCD2 mono-ubiquitination based on the PCNA ubiquitination assay. 
The combination of the FANCD2, PCNA and cell-based assays revealed 11 compounds that might specifically 
inhibit FANCD2 mono-ubiquitination, or that at least are not pan ubiquitination inhibitors.
FANCD2 foci formation. FANCD2 foci formation is often used as an indicator of FA core complex func-
tionality40,43. Therefore, we selected 11 compounds to test at 1 µM in 384-well format for their ability to reduce 
FANCD2 foci formation in SUM149 parental BRCA1-deficient cells. These 11 compounds were selected (Sup. 
Fig. 1) because they demonstrated a potential specific reduction in FANCD2 mono-ubiquitination or prefer-
entially killed BRCA1-deficient cells. None of the 11 compounds (1 µM) significantly reduced FANCD2 foci 
formation, however positive control TAK243 did inhibit FANCD2 foci formation in SUM149 parental cells 
(TAK243 = 0.28 v DMSO = 3.80, p < 0.0001), while being highly toxic. We also used mitomycin C, which is known 
to result in increased FANCD2 foci formation40, and this was true for SUM149 parental cells (MMC = 5.45 v 
DMSO = 3.80, p < 0.0001). The increase in FANCD2 foci in the presence of mitomycin C validates this cell-based 
assay (Fig. 6) and helps to establish TAK243 as a control inhibitor for FANCD2 mono-ubiquitination both with 
recombinant protein and in cells50. We included four effective PARP inhibitors, veliparib, rucaparib, olaparib 
and niraparib, to assess their effect on FANCD2 foci formation and found all increased FANCD2 foci formation 
in SUM149 parental cells (BRCA1-deficient) but not in SUM149 B1.S* (with one functional copy of BRCA1) 
(Fig. 6). The PARP inhibitor-dependent increase in FANCD2 foci formation suggests that these compounds 
increase the reliance of cells on the canonical FA pathway in these BRCA1-deficient cells, but not their isogenic 
BRCA1-proficient counterparts. An inhibitor of the FA pathway could exploit this dependency of FANCD2 activ-
ity to synergise with PARP inhibitors.
In summary this study shows a new tool for high-throughput screening with a functional reconstituted FA 
core complex. In the future, the development of targeted therapies may well benefit from the use of this screening 
tool when coupled with testing of diverse compound libraries and targeted molecules guided by structural data 
for the human FA core complex and FANCD2-FANCI.
Figure 5. Synthetic lethality ability of the 25 lead compounds. Synthetic lethality was assessed by performing 
a SRB Cell viability assay on SUM149 parental (BRCA1-negative) and SUM149 (BRCA1 reversion) in 
the presence of 25 lead inhibiting compounds at a concentration of 10 µM. * = P < 0.05, ** = P < 0.01, 
** = < 0.0001, n = 3.
8Scientific RepoRtS |         (2020) 10:7959  | https://doi.org/10.1038/s41598-020-64868-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Methods
Recombinant FA core complex. Cloning of MultiBAC expression vectors. Xenopus laevis FANCD2 was 
cloned into pDEST20-GST, resulting in a N-terminal tagged GST-FANCD2 and was co-purified with XlFANCI. 
The other proteins were human proteins and the cloning of the relevant plasmids was described previously26,51,52.
Protein production and purification. FANC-B-L-100 complex purification: High-Five cells were infected 
with BL100 virus at MOI of 2 and after 72 hrs were harvested by centrifugation at 500 g for 5 mins. Cells were 
resuspended in buffer A (20 mM Triethanolamine pH 7.5, 10% glycerol, 150 mM NaCl, 1 mM EDTA, mammalian 
protease inhibitors (Sigma P8340)). Cells were lysed by sonication and lysates were centrifuged at 18,000 g for 
30 mins. M2 ANTI-FLAG resin (Sigma A2220–10ML) was washed with 5 column volumes of buffer B (20 mM 
Triethanolamine pH 7.5, 10% glycerol, 150 mM NaCl) then 3 column volumes of 100 mM Glycine pH 3.5 and 
equilibrated with 5 column volumes of buffer B. The clarified lysate was added to the resin and incubated at 4 °C 
for 90 mins with gentle mixing. Resin was then washed with buffer B and FANC-B-L-100 was eluted in 1 column 
volume of 100 µg/ml FLAG peptide in buffer B at a concentration of 0.5 mg/ml.
FANCI and FANCD2 complex purification: High-Five cells were co-infected with FLAG-FANCI and 
GST-FANCD2 viruses each with a MOI of 1 and after 72 hrs were harvested by centrifugation at 500 g for 5 mins. 
Cells were resuspended in buffer and after sonication lysates were centrifuged at 18,000 g for 30 mins. Glutathione 
sepharose 4B resin (GE Healthcare, 17–0756–01) was equilibrated with buffer B according to the manufacturer’s 
instructions. Clarified lysate was added to the glutathione sepharose resin and incubated at 4 °C for 90 mins with 
gentle mixing. Sepharose was washed with 25 column volumes of buffer B. Elution was performed with 3 column 
volumes of buffer B with 40 mM reduced glutathione. Protein was then loaded onto equilibrated M2 flag resin and 
cycled through the column for 30 mins at 4 °C. Resin was washed with buffer B and FANCD2-FANCI heterodi-
mer was eluted with 1 ml fractions of 100 µg/mL FLAG peptide in buffer B. Fractions containing ID2 were pooled 
and aliquoted. Protein concentration was ~0.3 mg/ml. FAN-C-E-F complex purification was described previ-
ously26. UBE2T/FANCT purification: Steps were carried out at 4 °C. BL21 (DE3) E. coli cells expressing UBE2T 
(15 g paste) were lysed in 75 mL of CBB buffer containing 500 mM KCl with 0.1% IGEPAL, sonicated (3 ×5 mins 
Branson 450 power setting 2) and clarified (40,000 g x 30 mins). The cleared lysate was diluted with an equal vol-
ume of T buffer (25 mM Tris-HCl, 10% glycerol, 0.5 mM EDTA, 0.01% IGEPAL, 1 mM DΤΤ, and protease inhib-
itors) with 300 mM KCl and then mixed with 3 mL Glutathione-Sepharose beads for 1.5 hours. The affinity beads 
were washed with 50 mL each of T buffer with 500 mM KCl and T buffer with 1 M KCl, before being treated with 
18 mL T buffer with 100 mM KCl and PreScission protease overnight 4 °C. The eluate was passed through a 120 
uL complete His Tag resin (Roche) equilibrated with T buffer with 100 mM KCl to remove PreScission protease. 
The cleaved GST-UBE2T was passed over fresh Glutathione-Sepharose beads to ensure removal of GST-Ube2T 
or free GST. Ubiquitin with an N-terminal-conjugated biotin was produced with one of two methods, both which 
produced similar results. The first method is described previously52 or with the following method: Ubiquitin 
(Boston Biochemicals) was dissolved in water to give 10 mg/ml solution. EZ-L (EZ-Link-Silfo-NHS-Biotin 
(EZ-L) Thermo) was dissolved in dry DMSO (Molecular Probes) to give 10 mg/ml. One mL of ubiquitin solution 
was diluted with 30 mL 0.1 M NaPO4, pH 3.5 and added to 2 mL EZ-L solution incubated overnight at 37 °C. The 
reaction was stopped with 2 mL 1 M Trifluoroacetic acid (TFA). Reaction products were separated using HPLC 
with a Vydac C18 10 ×250 (218TP510 Vydac) column with a 40–80% buffer B gradient for 40 minutes at 2.5 mL/
min. Buffer A was 0.1% TFA in water. Buffer B was 0.1% TFA in 70% acetonitrile. Peaks were collected and sub-
mitted for MS/MS analysis to isolate the fraction with N-terminal biotinylated ubiquitin.
Figure 6. FANCD2 foci. FA pathway activity was assayed by immunofluorescence of FANCD2 foci. 11 
compounds (1 µM) identified from the inhibitor screen were analysed.
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Mono-ubiquitination proximity assay and compound libraries. For high-throughput screening, 
FANCD2 mono-ubiquitination was measured with a proximity assay (AlphaScreen, Perkin Elmer). The donor 
and acceptor beads are coated in streptavidin and anti-GST respectively. Therefore, when biotinylated ubiqui-
tin is conjugated onto GST-FANCD2 this brings the two beads into close proximity. Light at 680 nm is used 
to excite the donor bead, which transfers an oxygen singlet to the acceptor bead which emits detectable light 
at 520–620 nm. The 520–620 nm signal provides a read out of FANCD2 mono-ubiquitination. The ubiquitina-
tion proximity assays were performed in 7 µL reactions in 384-well AlphaPlates (Perkin Elmer). A master mix 
was prepared for ubiquitination assay. The inhibitor screen master mix contained 30 nM biotinylated ubiqui-
tin, 9.1 nM ubiquitin activating enzyme (Boston Biochem), 94.5 nM of FANCT, 86 nM FANC-B-L-100 complex, 
25 nM FANCD2-FANCI heterodimer, 93.1 nM FANC-C-E-F complex, 2.4 ng/mL 60 bp dsDNA. Five microlitres 
of master mix was incubated with 15 nL of a 5 mM compound stock (Compounds Australia, Griffith University) 
in DMSO, which corresponded to a final concentration of 0.2% DMSO. A total of 9,067 compounds were selected 
from two libraries, described previously53,54, from Compounds Australia. The first library – the Open Access 
Drug library – contained 2,667 compounds of primarily FDA-approved drugs. The second library, the Open 
Collection Scaffold library, was used to screen a selection of 6,400 compounds representing approximately 1,000 
scaffold bases. All protein concentrations in the assay were determined by titration of each component for opti-
mal activity (Fig. 2). Reaction mixtures were left to incubate with compound for 30 minutes before the reaction 
was started by adding ATP to a final concentration of 1.14 mM. The FANC-C-E-F complex was omitted from the 
activator screen mastermix. The inhibitor and activator screen reactions proceeded for 90 mins and 240 mins, 
respectively. Reactions were stopped by adding a 5 µL working solutions of streptavidin donor beads, immediately 
followed by 5 µL of anti-GST acceptor beads (Perkin Elmer), each at a final concentration of 0.06%. The controls 
for the inhibitor assay were 0.2% DMSO (vehicle), 0.2% DMSO plus 10 µM TAK243 ubiquitin activating enzyme 
inhibitor (positive control inhibitor) and no ATP (control for background signal). The activator assay controls 
were 0.2% DMSO (vehicle), 0.2% DMSO plus FANC-C-E-F (positive control activator) and no ATP (control for 
background signal). All of the liquid handling steps were performed robotically on a Sciclone ALH 300 (Caliper 
Life Sciences, Perkin Elmer). The ubiquitination master mixes, ATP working stock and acceptor and donor bead 
solutions were prepared in 384 deep-well master plates, in which respective volumes were transferred from these 
master plates to an assay plate using the Sciclone ALH300 to reduce reagent wastage. Between four and 11 assay 
plates were performed at a time with 160 compounds on each plate. All compounds in the primary screen were 
analysed in duplicate. Plate columns 1, 2 and 23 contained DMSO and activator and inhibitor controls. Column 
24 contain No ATP. Data from each plate was normalised to using moving average z-scores (z-score = (sample 
raw score – population mean)/population standard deviation). Moving average was calculated using a radius 
of four wells around each sample to account for plate and edge effects. Activating and inhibiting compounds to 
carry forward to secondary screening were defined as those that had less than 30% variance between duplicates 
had z-scores greater than 2 or less than −2, respectively. A 9-point dose response was performed for secondary 
screening using a half-logarithmic dilution series. Percentage inhibition and activation was calculated for respec-
tive dose-responses and compounds were ranked by area-under the curve calculations (AUC). AUC was used 
instead of IC50/AC50 as some compounds demonstrated inhibition or activation but did not reach 50% inhibi-
tion or activation within this concentration range tested. IC50 values and R2 values are in Sup. Table 1. Plates were 
read on an Enspire (Perkin Elmer).
Cell lines and culture conditions. SUM149 parental cells and SUM149 B1.S* cells49 were cultured 
in Hams-F12 from Gibco supplemented with 10% fetal bovine serum, 0.24 IU/mL of Insulin, 50 ng/mL 
Hydrocortisone and 1X penicillin/streptomycin. Both cells lines were grown at 37 °C in a 5% CO2 atmosphere. 
Insect cell lines. High Five cells (Invitrogen) were cultured in Sf-900II SFM media from Gibco and were incubated 
at 27 °C, shaking.
Synthetic lethal cell assay. SUM149 parental cell line and SUM149 B1.S* cell lines49 were seeded in a 
96-well plate with 3000 cells per well. After 24 h, media was removed, and the cells were treated with 10 µM of 
each compound in triplicate in antibiotic free media and left for 72 h. Cell were fixed with 1% trichloroacetic acid 
and stained with sulphorhodamine B (SRB). Absorbance of wells were read at 550 nm.
Detection of nuclear FANCD2 foci. Nuclear FANCD2 foci were measured in high throughput by quanti-
tating DAPI stained cell nuclei of either SUM149 or SUM149 B1.S* cell lines using automated confocal imaging 
(CX7 LZR, ThermoFisher Scientific). Control DMSO, treated cells reached 85% confluence at the conclusion of 
2 days of 1 µM drug exposure. FANCD2 foci were detected with immunofluorescence using rabbit anti-human 
FANCD2 (abcam, ab108928). 1 µM was selected in order to have sufficient nuclei for FANCD2 foci quantification, 
as 10 µM compounds was too toxic for certain compounds.
Received: 29 January 2020; Accepted: 23 April 2020;
Published: xx xx xxxx
References
 1. Garaycoechea, J. I. et al. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature 489, 
571–575 (2012).
 2. Langevin, F., Crossan, G. P., Rosado, I. V., Arends, M. J. & Patel, K. J. Fancd2 counteracts the toxic effects of naturally produced 
aldehydes in mice. Nature 475, 53–58 (2011).
 3. Alter, B. P. Cancer in Fanconi Anemia, 1927–2001. (2001). https://doi.org/10.1002/cncr.11046
 4. Kutler, D. I. et al. High incidence of head and neck squamous cell carcinoma in patients with Fanconi anemia. Arch. Otolaryngol. - 
Head Neck Surg. 129, 106–112 (2003).
 5. Tsui, V. & Crismani, W. The Fanconi Anemia Pathway and Fertility. Trends Genet. 35, 199–214 (2019).
1 0Scientific RepoRtS |         (2020) 10:7959  | https://doi.org/10.1038/s41598-020-64868-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
 6. Meetei, A. R. et al. X-linked inheritance of Fanconi anemia complementation group B. Nat. Genet. 36, 1219–1224 (2004).
 7. Wang, A. T. et al. A Dominant Mutation in Human RAD51 Reveals Its Function in DNA Interstrand Crosslink Repair Independent 
of Homologous Recombination. Mol. Cell 59, 478–490 (2015).
 8. Auerbach, A. D. Fanconi anemia and its diagnosis. Mutat. Res. - Fundam. Mol. Mech. Mutagen. 668, 4–10 (2009).
 9. Frohnmayer, D., Frohnmeyer, L., Guinan, E., Kennedy, T. & Larsen, K. Fanconi Anemia: Guidelines for Diagnosis and Management. 
4th ed. Fanconi Anemia Research Fund, Inc. (2014).
 10. Shimamura, A. & Alter, B. P. Pathophysiology and management of inherited bone marrow failure syndromes. Blood Rev. 24, 101–122 (2010).
 11. Shimamura, A. et al. A novel diagnostic screen for defects in the Fanconi anemia pathway. Blood 100, 4649–4654 (2002).
 12. Paquin, K. L. et al. FANCD2 Binding to H4K20me2 via a Methyl-Binding Domain Is Essential for Efficient DNA Cross-Link Repair. 
Mol. Cell. Biol. 39, 1–14 (2019).
 13. Río, P. et al. Successful engraftment of gene-corrected hematopoietic stem cells in non-conditioned patients with Fanconi anemia. 
Nat. Med. 25, 1396–1401 (2019).
 14. Zhang, H. et al. TGF-β Inhibition Rescues Hematopoietic Stem Cell Defects and Bone Marrow Failure in Fanconi Anemia. Cell Stem 
Cell 18, 668–681 (2016).
 15. Kais, Z. et al. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair. 
Cell Rep. 15, 2488–2499 (2016).
 16. Kao, W. H. et al. Upregulation of Fanconi Anemia DNA Repair Genes in Melanoma Compared with Non-Melanoma Skin Cancer. 
J. Invest. Dermatol. 131, 2139–2142 (2011).
 17. Michl, J., Zimmer, J., Buffa, F. M., McDermott, U. & Tarsounas, M. FANCD2 limits replication stress and genome instability in cells 
lacking BRCA2. Nat. Struct. Mol. Biol. 23, 755–757 (2016).
 18. Nijman, S. M. B. et al. The deubiquitinating enzyme USP1 regulates the fanconi anemia pathway. Mol. Cell 17, 331–339 (2005).
 19. Lim, K. S. et al. USP1 Is Required for Replication Fork Protection in BRCA1-Deficient Tumors. Mol. Cell 72, 925–941.e4 (2018).
 20. Lord, C. J. & Ashworth, A. PARP inhibitors: Synthetic lethality in the clinic. Science (80-.). 1158, 1152–1158 (2017).
 21. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467–480 (2011).
 22. Ceccaldi, R., Sarangi, P. & D’Andrea, A. D. The Fanconi anaemia pathway: new players and new functions. Nat. Rev. Mol. Cell Biol. 
17, 337–349 (2016).
 23. Schlacher, K. et al. Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by 
MRE11. Cell 145, 529–542 (2011).
 24. Schlacher, K., Wu, H. & Jasin, M. A Distinct Replication Fork Protection Pathway Connects Fanconi Anemia Tumor Suppressors to 
RAD51-BRCA1/2. Cancer Cell 22, 106–116 (2012).
 25. Schwab, R. A. et al. The Fanconi Anemia Pathway Maintains Genome Stability by Coordinating Replication and Transcription. Mol. 
Cell 60, 351–361 (2015).
 26. Van Twest, S. et al. Mechanism of Ubiquitination and Deubiquitination in the Fanconi Anemia Pathway. Mol. Cell 65, 247–259 (2017).
 27. Swuec, P. et al. The FA Core Complex Contains a Homo-dimeric Catalytic Module for the Symmetric Mono-ubiquitination of 
FANCI-FANCD2. Cell Rep. 18, 611–623 (2017).
 28. Alpi, A. F., Pace, P. E., Babu, M. M. & Patel, K. J. Mechanistic Insight into Site-Restricted Monoubiquitination of FANCD2 by Ube2t, 
FANCL, and FANCI. Mol. Cell 32, 767–777 (2008).
 29. Rajendra, E. et al. The Genetic and Biochemical Basis of FANCD2 Monoubiquitination. Mol. Cell 54, 858–869 (2014).
 30. Shakeel, S. et al. Structure of the Fanconi anemia monoubiquitin ligase complex. Nature 1–46 https://doi.org/10.1038/s41586-019-
1703-4 (2019).
 31. Benitez, A. et al. FANCA Promotes DNA Double-Strand Break Repair by Catalyzing Single-Strand Annealing and Strand Exchange. 
Mol. Cell 1–8 https://doi.org/10.1016/j.molcel.2018.06.030 (2018).
 32. Garcia-Higuera, I., Kuang, Y., Denham, J. & D’Andrea, A. D. The fanconi anemia proteins FANCA and FANCG stabilize each other 
and promote the nuclear accumulation of the Fanconi anemia complex. Blood 96, 3224–3230 (2000).
 33. Chirnomas, D. et al. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway. Mol. Cancer Ther. 5, 
952–961 (2006).
 34. Jacquemont, C., Simon, J. A., D’Andrea, A. D. & Taniguchi, T. Non-specific chemical inhibition of the Fanconi anemia pathway 
sensitizes cancer cells to cisplatin. Mol. Cancer 11, 26 (2012).
 35. Landais, I. et al. Monoketone analogs of curcumin, a new class of Fanconi anemia pathway inhibitors. Mol. Cancer 8, 133 (2009).
 36. Landais, I., Sobeck, A., Stone, S., LaChapelle, A. & Hoatlin, M. E. A novel cell-free screen identifies a potent inhibitor of the Fanconi 
anemia pathway. Int. J. Cancer 124, 783–792 (2009).
 37. Cornwell, M. J. et al. Small Molecule Inhibition of UBE2T/FANCL-mediated Ubiquitylation in the Fanconi Anemia Pathway. ACS 
Chem. Biol. https://doi.org/10.1021/acschembio.9b00570 (2019).
 38. Hyer, M. L. et al. A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment. Nat. Med. 24, 186–193 (2018).
 39. Timmers, C. et al. Positional cloning of a novel Fanconi anemia gene, FANCD2. Mol. Cell 7, 241–248 (2001).
 40. Garcia-Higuera, I. et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001).
 41. Morreale, F. E. et al. Allosteric targeting of the Fanconi anemia ubiquitin- conjugating enzyme Ube2T by fragment screening 
Allosteric targeting of the Fanconi anemia ubiquitin-conjugating en- zyme Ube2T by fragment screening. (2017).
 42. Bogliolo, M. et al. Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. 
J. Med. Genet. 1–11 https://doi.org/10.1136/jmedgenet-2019-106249 (2019).
 43. Meetei, A. R. et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat. Genet. 35, 165–170 (2003).
 44. Jung, M. et al. Association of clinical severity with FANCB variant type in Fanconi anemia. Blood https://doi.org/10.1182/
blood.2019003249 (2020).
 45. Hira, A. et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause fanconi anemia. Am. J. Hum. Genet. 96, 
1001–1007 (2015).
 46. Virts, E. L. et al. AluY-mediated germline deletion, duplication and somatic stem cell reversion in UBE2T defines a new subtype of 
Fanconi anemia. Hum. Mol. Genet. 24, 5093–5108 (2015).
 47. Rickman, K. A. et al. Deficiency of UBE2T, the E2Ubiquitin Ligase Necessary for FANCD2 and FANCI Ubiquitination, Causes FA-T 
Subtype of Fanconi Anemia. Cell Rep. 12, 35–41 (2015).
 48. Elstrodt, F. et al. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 
66, 41–45 (2006).
 49. Dréan, A. et al. Modelling therapy resistance in BRCA1/2 mutant cancers. Mol. Cancer Ther. 16, molcanther.0098.2016 (2017).
 50. Niraj, J., Färkkilä, A. & D’Andrea, A. D. The Fanconi Anemia Pathway in Cancer. Annu. Rev. Cancer Biol. 3, 457–478 (2019).
 51. Tan, W. et al. Preparation and purification of mono-ubiquitinated proteins using Avi-tagged ubiquitin. PLoS One 15, e0229000 (2020).
 52. Tan, W. et al. Monoubiquitination by the human Fanconi Anemia core complex clamps FANCI:FANCD2 on DNA in filamentous 
arrays. Elife 9, (2020).
 53. Simpson, M. & Poulsen, S. A. An overview of Australia’s compound management facility: The Queensland compound library. ACS 
Chem. Biol. 9, 28–33 (2014).
 54. Preston, S. et al. Screening of the ‘Open Scaffolds’ collection from Compounds Australia identifies a new chemical entity with 
anthelmintic activities against different developmental stages of the barber’s pole worm and other parasitic nematodes. Int. J. 
Parasitol. Drugs Drug Resist. 7, 286–294 (2017).
1 1Scientific RepoRtS |         (2020) 10:7959  | https://doi.org/10.1038/s41598-020-64868-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
Thank you to Rohan Bythell-Douglas for helpful comments on the manuscript. This work has been supported by 
funding from the National Health and Medical Research Council (Career development fellowship GNT1129757 
to W.C., a project grant GNT1156343 awarded to W.C., A.J.D. and K.J.S.), Maddie Riewoldt’s Vision (MRV 
Fellowship WC-MRV2016 to W.C. and Grant-In-Aid SVI-MRV2017G to W.C. and A.D.), the Victorian Cancer 
(Victorian Cancer Agency Fellowship to A.J.D.) and the Victorian government IOS program. W.T. was supported 
by an Australian Government Research Training Scheme postgraduate scholarship. The Victorian Centre for 
Functional Genomics (K.J.S.) is funded by the Australian Cancer Research Foundation (ACRF), the Australian 
Phenomics Network (APN) through funding from the Australian Government’s National Collaborative Research 
Infrastructure Strategy (NCRIS) program, the Peter MacCallum Cancer Centre Foundation and the University of 
Melbourne Research Collaborative Infrastructure Program. We thank Compounds Australia Griffith University 
for their provision of specialized compound management and logistics services to the project. Griffith is a 
recipient of Queensland Government “Smart State Research Facilities Fund” funding and Australian Government 
funding provided under the “Super Science Initiative” and financed from the Education Investment Fund. The 
SUM149 and SUM149 B1.S* cells were a gift from Stephen Pettitt and Christopher Lord.
Author contributions
M.S., W.C., K.S., A.D. conceived the experiments. M.S., W.C., S.V.T., V.M., W.T., J.L. performed the experiments. 
M.S., W.C., and K.S. analysed the data. M.S. and W.C. wrote the manuscript. M.S. and W.C. prepared the figures. 
All authors reviewed the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-64868-7.
Correspondence and requests for materials should be addressed to W.C.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
